Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPC-7869 Phase 3 in mild Alzheimer's disease
NCT00105547Phase 3Completed
- Sponsor
- Myrexis, Inc.
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tarenflurbil in Alzheimer's disease (AD), sponsored by Myrexis, Inc.. Started Feb 2005; status: completed.
02
Drugs
tarenflurbil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00105547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105547.